Fascin在结肠癌中表达的临床病理学研究

目的:Fascin是一种肌动蛋白结合蛋白,在多种上皮性肿瘤中高表达并与肿瘤侵袭有关。在本研究中观察fascin在结肠癌中表达及探讨其临床病理意义,为其在结肠癌早期诊断和预后预测方面的应用提供依据。方法:应用免疫组织化学技术检测Fascin在结肠肿瘤中的表达,并分析其表达的结肠癌临床病理意义。结果:Fascin在癌旁肠粘膜、腺瘤、腺癌中表达有显著性差异,其中癌旁肠粘膜组和腺瘤组阳性表达率无显著性差异(X2=0.344,P0.05),腺癌组阳性表达率显著高于癌旁粘膜组(X2=8.492,P0.0,1),腺癌组阳性表达率显著高于腺瘤组(X2=7.450,P0.01)。Fascin表达与结肠癌患者的年龄、性别、肿瘤浸润肠壁深度、淋巴结转移、分化程度无显著相关性,而在中-晚期病例(III/IV期)中的表达率显著高于早期病例(P0.05)。Fascin表达阳性病例的生存期显著高于Fascin表达阴性病例(P0.022)。结论:Fascin表达与结肠癌发生和预后密切相关,可能作为结肠癌早期诊断和预后的标志物。

Clinicopathological Study of Fascin Expression in Colon Carcinoma

ABSTRACT Objective:Fascin is an actin binding protein, was highly expressed in a variety of epithelial tumors and was associated with tumor invasion. We will observe expression of Fascin and explore its clinicopathological significance in colon cancer in this study to provide a basis for its application in colon cancer early diagnosis and prognosis prediction.Methods: Expression of Fascin detected by immunohistochemical method in colon cancer, and to analyze its expression in colon cancer clinicopathological significance. Results:Fascin in paracancer mucosa, adenoma, adenocarcinoma had significant difference among the expression, paracancer mucosa and adenoma group expression had no significant difference (X2=0.344, P>0.05), adenocarcinoma positive expression rate was significantly higher than that in paracancerous mucosa group (X2=8.492, P<0.0,1), adenocarcinoma positive group the expression rate was significantly higher than that of adenoma group (X2=7.450, P<0.01). The expression of Fascin in patients with colon cancer age, gender, tumor invasion depth of bowel wall, lymph node metastasis, and degree of differentiation has no significant correlation, cases in middle - late stage (stage III/IV) in the expression rate was significantly higher than the early cases (P<0.05). The expression of Fascin positive cases, survival was significantly higher than that in Fascin negative expression patients (P<0.022).Conclusion: Fascin expression is closely associated with the occurrence and prognosis of colon cancer, and may be biomarker for the early stage diagnosis and prognosis.